LabCorp's Covance Mobile Health Solutions Augment Clinical Trials
BURLINGTON, NC: Laboratory Corporation of America (LabCorp) declares that its Covance Drug Development (Covance) has unlocked Mobile Health Solutions that conveys seamless supports to biopharmaceutical and technology companies in navigating the proliferation of mobile healthcare services. Covance’s newly launched solutions delivers regulatory consulting and validation services that lead pharmaceutical industries to certificating based on their accuracy and consistency of mobile devices and applications for clinical trials.
“Mobile technology is changing the way patients interact with their healthcare providers, and clinical trials must adapt as well. Covance has the expertise and scale to help our partners evaluate which apps and devices will be most effective, will generate the most consistent and reliable data and will be easy for patients to use,” says Deborah Keller, Chief Executive Officer of Covance.
LabCorp supplies comprehensive clinical laboratory services through LabCorp diagnostics, and end-to-end drug development support through Covance Drug Development. It also ranks well in commercializing and improving new diagnostic technologies to make people healthier by offering a single platform with the combination of world-class diagnostics, drug development and knowledge services. Its services have been spreading almost across 60 countries. The company’s unlocked mobile health devices and apps will lead industries to use it in multiple methodologies for improving patient’s accesses, produce and maintain longitudinal data measurements as well as generate more powerful data analytics. The enhancement of mobile technologies in heath care relies on global acceptances of its growing demand, therefore the Covance regulatory experts help clients to determine their tracks for mobile health validation, registration and approval for use in clinical trials.
“Covance is committed to helping clients leverage mobile technology to improve the success of clinical trials and enhance the patient experience. Our Mobile Health Solutions support our strategic vision to improve health and improve lives through the use of technology-enabled solutions that enhance the drug-development process and can reduce the time and cost of trials,” adds Keller.
By James Seevers, CIO & GM, Toyoda Gosei
By Bill Krivoshik, SVP & CIO, Time Warner Inc.
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Bruce. D. Smith, SVP & CIO, Information Systems, Advocate...
By Adrian Mebane, VP-Global Ethics & Compliance, The Hershey...
By Graham Welch, Director-Cisco Security, Cisco
By Michael Watkins, Senior Product Director, Global Knowledge
By Bernd Schlotter, President of Services, Unify
By Patrick Hale, CIO, VITAS Healthcare
By Steve Bein, VP-GIS, Michael Baker International
By Jason Alan Snyder, CTO, Momentum Worldwide
By Mike Morris, CIO, Legends
By Louis Carr, Jr., CIO, Clark County
By Bill Dow, SVP and General Manager of Business Solutions,...
By Jim Whitehurst, CEO, Red Hat
By Darren Cockrel, CIO, Coyote Logistics, a UPS Company...
By Nathan Johnson, SVP and CIO, Werner Enterprises [NASDAQ:...
By David Tamayo, CIO, DCS Corporation
By Neil Hampshire, CIO, ModusLink Global Solutions, Inc....